Streetbeat News

Stock Prices

AKBA

Akebia Therapeutics (NASDAQ:AKBA) is scheduled to release its quarterly earnings report on March 14, 2024, with an expected EPS of $-0.04. Investors are hopeful for a beat on this estimate and positive guidance for the next quarter. Historical data shows a correlation between earnings performance and stock price movement. Shares have risen 105.59% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:05 pm

AVD

American Vanguard (NYSE:AVD) is scheduled to release its quarterly earnings report on March 14, 2024, with analysts expecting an EPS of $0.27. The company's past earnings performance shows mixed results, with a notable miss last quarter but a subsequent share price increase. Shares are currently trading at $10.82, down 48.46% over the last year. Investors are keenly awaiting the report and guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:05 pm

ULTA

Ulta Beauty (NASDAQ:ULTA) is expected to report an EPS of $7.52 in its upcoming quarterly earnings on March 14, 2024. Analysts and investors are particularly focused on whether the company will surpass this estimate and provide positive guidance for future growth. Historical data shows Ulta Beauty's stock price reacts significantly to earnings performance and guidance. Last quarter, ULTA beat the EPS estimate by $0.12, leading to a 10.81% stock price increase the following day. Over the past year, ULTA shares have risen by 8.8%, with the stock currently trading at $555.57.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:04 pm

RMBL

RumbleON (NASDAQ:RMBL) is scheduled to release its quarterly earnings report on March 14, 2024, with analysts expecting an EPS of $-0.51. The company's past earnings performance shows a mix of misses and beats against estimates, with the stock price reacting variably. Shares are currently trading at $7.31, down 9.48% over the last year. Investors are looking for positive guidance for the next quarter beyond the earnings beat or miss.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:04 pm

CSIQ

Canadian Solar (NASDAQ:CSIQ) is scheduled to release its quarterly earnings report on March 14, 2024. Analysts predict an EPS of $0.00. The company's past earnings performance shows a mix of misses and beats, with the share price reacting accordingly. Shares are currently trading at $20.22, down 44.31% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:04 pm

EVCM

EverCommerce (NASDAQ:EVCM) is scheduled to release its quarterly earnings report on March 14, 2024. Analysts predict an EPS of $0.13. The company's past earnings performance shows a mix of misses and beats, with the stock price reacting accordingly. Shares are currently trading at $9.75, down 8.93% over the last year. Investors are advised to watch for the earnings outcome and particularly the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:04 pm

BLNK

Blink Charging (NASDAQ:BLNK) is scheduled to release its quarterly earnings report on March 14, 2024, with analysts expecting an EPS of $-0.31. The company's past performance shows a pattern of beating EPS estimates, leading to significant share price movements. Shares are currently trading at $3.14, down 58.55% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:04 pm

NBIX

Neurocrine Biosciences (NASDAQ:NBIX) has been evaluated by 8 analysts over the past three months, showing a mix of bullish to bearish sentiments. The average 12-month price target is $151.88, marking a 7.72% increase from the previous target. Analysts from firms like Oppenheimer and JP Morgan have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Neurocrine Biosciences, a pharmaceutical company, has shown a 25.05% revenue growth rate as of December 31, 2023, but faces challenges in profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:04 pm

ENFN

Four analysts have recently updated their ratings on Enfusion (NYSE:ENFN), showing a mix of underperform and sell recommendations, with price targets ranging from $8.00 to $10.00. This reflects a slight decline in the average price target to $9.00, down 2.7% from the previous average. Enfusion, a SaaS provider for the investment management industry, has shown a 13.3% revenue growth rate as of September 30, 2023, but its market capitalization and growth rate are below industry benchmarks. Despite this, the company has an exceptional net margin of 4.13%, an ROE of 3.7%, and an ROA of 1.87%, indicating strong profitability and financial health.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:04 pm

GETY

Getty Images Holdings (NYSE:GETY) is set to release its quarterly earnings report on March 14, 2024, with an estimated EPS of $0.01. Historical performance shows a pattern of not meeting EPS estimates, leading to negative stock price reactions. Shares are currently trading at $4.96, with an 8.8% increase over the last 52 weeks. Investors are looking for not just an earnings beat but also positive future guidance.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 2:04 pm